News | January 07, 2010

Isolated Lytic, Aspiration DVT Treatment Reduces Hospital Stays

January 7, 2010 – Doctors with Virginia Interventional and Vascular Associates (VIVA) report success in treating acute deep vein thrombosis (DVT) with a procedure called isolated pharmacomechanical thrombolysis (IPMT). The treatment has been used for the past two years to destroy clots much faster than traditional therapies.

VIVA performs the two-hour, minimally invasive procedure with the FDA-cleared Trellis Peripheral Infusion System. Using images to help guide Trellis to the right spot, VIVA's interventional radiologists isolate the clot with balloons positioned at each end of the catheter, infuse the clot with fibrinolytic medication, break it up with a tiny rotating wire, and aspirate the remaining particles.

John D. Statler, M.D., an interventional radiologist with VIVA, says the procedure offers several advantages over traditional therapies such as anti-coagulant medication. This prevents the clot from growing and protects the lungs, but does not dissolve the clot, relying on the body to break it down over time. Catheter-directed thrombolysis, which dissolves clots by delivering thrombolytic medication through catheters, requires a 24- to 72-hour intensive care hospital stay.

"We can destroy the clot and relieve pain for most patients within a couple of hours after starting the procedure," Dr. Statler said. "It requires an overnight hospital stay, rather than intensive care for several days, and the risk of bleeding is lower than for catheter-directed thrombolysis."

Dr. Statler said the safety and effectiveness of IPMT was documented in several clinical studies. The American College of Chest Physicians has endorsed the procedure for select patients with extensive acute proximal DVT.

While DVT is not fatal by itself, a blood clot that travels to the pulmonary arteries, a pulmonary embolism, can be deadly, according to the Office of the Surgeon General (OSG). Together, DVT and pulmonary embolism contribute to at least 100,000 deaths each year. The OSG, along with the National Quality Forum and The Joint Commission, has called for more aggressive treatment of DVT.
VIVA is the interventional radiology and vascular surgery division of Radiologic Associates of Fredericksburg, Va.

For more information: www.imagingway.com/dvt, www.vivassociates.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Overlay Init